Article Information
History
- September 25, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jerry Sadoff1 (jsadoff{at}its.jnj.com),
- Mathieu Le Gars2,11 (mathieu.legars1{at}gmail.com),
- Georgi Shukarev1 (gshukare{at}its.jnj.com),
- Dirk Heerwegh1 (dheerweg{at}its.jnj.com),
- Carla Truyers1 (ctruyers{at}its.jnj.com),
- Anna Marit de Groot1 (mgroot{at}its.jnj.com),
- Jeroen Stoop1 (jstoop1{at}its.jnj.com),
- Sarah Tete1 (stete{at}its.jnj.com),
- Wim Van Damme1 (wvandam4{at}its.jnj.com),
- Isabel Leroux-Roels3 (isabel.lerouxroels{at}uzgent.be),
- Pieter-Jan Berghmans4 (pieterjan.berghmans{at}sgs.com),
- Murray Kimmel5 (mkimmel{at}optimalsites.net),
- Pierre Van Damme6 (pierre.vandamme{at}uantwerpen.be),
- Jan De Hoon7 (jan.dehoon{at}uzleuven.be),
- William Smith8 (william.smith{at}amrllc.com),
- Kathryn Stephenson9 (kstephen{at}bidmc.harvard.edu),
- Dan Barouch9 (dbarouch{at}bidmc.harvard.edu),
- Stephen De Rosa10 (sderosa{at}fredhutch.org),
- Kristen Cohen10 (kwcohen{at}fredhutch.org),
- Juliana McElrath10 (jmcelrat{at}fredhutch.org),
- Emmanuel Cormier1 (ecormier{at}its.jnj.com),
- Gert Scheper1 (gscheper{at}its.jnj.com),
- Jenny Hendriks1 (jhendri1{at}its.jnj.com),
- Frank Struyf1 (fstruyf{at}its.jnj.com),
- Macaya Douoguih1 (mdouogui{at}its.jnj.com),
- Johan Van Hoof1 (jvhoof1{at}its.jnj.com) and
- Hanneke Schuitemaker1 (hschuite{at}its.jnj.com)
- 1 Janssen;
- 2 Janssen Vaccines and Prevention;
- 3 CEVAC - University of Gent;
- 4 SGS Life Sciences;
- 5 Optimal Research LLC;
- 6 CEV University of Antwerp;
- 7 CCP LUVAC UZ Leuven;
- 8 VRG and NOCCR;
- 9 Beth Israel Deaconess Medical Center;
- 10 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
- ↵* Corresponding author; email: mathieu.legars1{at}gmail.com
Posted September 25, 2020.
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
